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Abstract The concept that complex surgical procedures should be performed at high-volume centers to improve surgical
morbidity and mortality is becoming widely accepted. We wanted to determine if there were differences in the treatment of
patients with gastric cancer between community cancer centers and teaching hospitals in the United States. Data from the
2001 Gastric Cancer Patient Care Evaluation Study of the National Cancer Data Base comprising 6,047 patients with gastric
adenocarcinoma treated at 691 hospitals were assessed. The mean number of patients treated was larger at teaching hospitals
(14/year) when compared to community centers (5–9/year) (p<0.05). The utilization of laparoscopy and endoscopic
ultrasonography were significantly more common at teaching centers (p<0.01). Pathologic assessment of greater than
15 nodes was documented in 31% of specimen at community hospitals and 38% at teaching hospitals (p<0.01). Adjusted
for cancer stage, chemotherapy and radiation therapy were utilized with equal frequency at all types of treatment centers.
The 30-day postoperative mortality was lowest at teaching hospitals (5.5%) and highest at community hospitals (9.9%)
(p<0.01). These data support previous publications demonstrating that patients with diseases requiring specialized treatment
have lower operative mortality when treated at high-volume centers.
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Approximately 22,000 patients in the United States (US)
will be diagnosed with gastric carcinoma in 2006, a number
that pales in comparison to more common malignancies
such as colorectal (172,000 new cases) and breast cancer
(211,000 new cases).
1 Because of the relative infrequency
of gastric cancer, most individual hospitals evaluate and
treat a limited number of patients with stomach cancer,
impairing the ability to develop expertise at many institu-
tions. A lack of expertise may contribute to the dismal
survival of gastric cancer in the US. In an earlier report from
the National Cancer Data Base (NCDB), Hundahl et al.
2
observed a 5-year survival rate of 78% for stage IA, 58%
for stage IB, 34% for stage II, 20% for stage IIIA, 8% for
stage IIIB, and 7% for stage IV disease.
Ar e c e n tr e p o r tf r o mt h eW o r l dH e a l t hO r g a n i z a t i o n
3
shows a decline in the mortality of gastric cancer worldwide.
However, the observed rate of decline in mortality is less in
the US than what is observed for Japan. Factors that might
contribute to the improved Japanese survival includes greater
operative experience leading to more skilled surgeons, earlier
diagnosis, different biologies of gastric cancer between
countries, improved pathologic staging with stage migration
(Will Rogers effect),
4 and the frequency of neoadjuvant or
adjuvant chemoradiation therapy use.
These data highlight the need for improved treatment of
gastric cancer to increase patient survival. A controversial
way to accomplish this might be to limit gastric cancer care
to high-volume centers, if the results were better at such
sites. Evidence-based hospital referral has been adopted by
some insurance companies and consortiums of large health
care purchasers, such as the Leapfrog group, based on
studies showing better outcomes for surgical services at
high-volume centers.
5–7 Birkmeyer et al.
8 reported that
Medicare patients had a lower operative mortality if they
had cancer-related procedures (gastrectomy, esophagec-
tomy, colectomy, pancreatectomy, cystectomy, nephrecto-
my, and pulmonary resection) or cardiovascular disease at a
high-volume hospital. The Japanese have also found a
similar pattern of improved survival after the treatment of
gastric carcinoma at high-volume centers. Nomura et al.
9
reported 5-year survival rates to be significantly higher at
centers with high surgical volumes (96–205/year), when
compared to very-low-volume hospitals (1–28 cases/year).
To determine if patients treated for gastric cancer at
high-volume and specialized centers in the US had better
postoperative outcomes, we analyzed the preoperative
evaluation and surgical treatment of gastric adenocarcino-
ma at three categories of hospitals, defined by the
Commission on Cancer (CoC), namely, the Community
Hospital Cancer Program (CHCP), Community Hospital
Comprehensive Cancer Program (COMP), and Teaching
Hospital Cancer Program (THCP). Data collected for the
2001 Gastric Cancer Patient Care Evaluation (PCE) by the
NCDB were utilized.
Material and Methods
NCDB, Data Source, Case Selection, and Data Handling
The NCDB is a project of the American College of
Surgeons (ACS) CoC. The NCDB was established in
1989 to serve as a comprehensive clinical surveillance
resource for all forms of cancer diagnosed in the US and its
operations have been supported in part by the American
Cancer Society. In 2001, the database captured 73% of all
newly diagnosed cancer cases in the US.
Data were submitted electronically in accordance with
specified North American Association of Central Cancer
Registries data transmission standards.
10 Hospital cancer
registrars abstracted each case according to a standardized
set of data elements and definitions as described in the
CoC’s Registry Operations and Data Standards, volume
II.
11 The NCDB elements include patient characteristics:
sex, age or date of birth, and race/ethnicity; tumor
characteristics: primary site, histology, behavior, grade,
and American Joint Committee on Cancer (AJCC), fifth
edition stage groups; and first course of treatment: surgery,
radiation, chemotherapy, and others. In addition to the
annual call for data, a call for participation in a 2001 PCE
was issued and 711 of the 1,423 CoC-approved institu-
tions in the US responded. Cancer registrars were also
asked to provide information describing additional diag-
nostic and treatment information, 30-day mortality, and
patient comorbidities. Data quality checks were conducted
at the local and the depository level.
Patient Population
The 2001 Gastric PCE included data submitted from 711
CoC-approved institutions in the US. Participating institu-
tions submitted data for consecutive hospital admissions
and clinic visits between January 1, 2001 and December 31,
2001. Patients eligible for participation had a “microscop-
ically confirmed neoplasm of the stomach that was either
diagnosed or initially treated at the reporting facility.” Of
7,084 total patients, 6,099 (86%) were diagnosed with
gastric adenocarcinoma. For this study, 52 patients were
excluded because they were treated at nine institutions
without a specialized hospital type, leaving 6,047 patients
at 691 cancer program types for evaluation. This group
comprises the study population.
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Cancer programs were characterized as CHCP, COMP, or
THCP. Community Hospital Cancer Programs diagnose
and/or treat 100–650 cancer patients every year and will
commonly refer patients to other institutions for diagnostic
evaluation or treatment. A CHCP has neither a medical
school affiliation nor residency programs but does posses a
medical oncology unit or functional equivalent and infre-
quently participates in cancer research. Community Hospi-
tal Comprehensive Cancer Programs diagnose and/or treat
more than 650 cancer cases per year, but are not associated
with a medical school. A COMP may make outside patient
referrals, has a medical oncology unit, and participates in
cancer research. Teaching Hospital Cancer Programs are
defined as facilities associated with a medical school that
participates in the training of residents in at least four
fields, two of which are medicine and surgery. A THCP
offers a full range of diagnostic and therapeutic services
on site and has an in-patient medical oncology unit. A
THCP hospital also participates in cancer-related clinical
research and has board-certified medical oncologists.
Statistical Analysis
All analyses were performed using the SPSS statistical
software (SPSS for Windows, version 14.0; SPSS Inc,
Chicago, IL, USA). Frequency distributions were calculated
to get the mean number of cases by hospital category type.
The chi-square (χ
2) test was used for comparisons of
proportions across levels of categorical variables. When the
overall test was significant, pairwise comparisons among
the three hospital categories were also calculated to asses
which hospitals differed in rates. The p values reported were
adjusted for multiple comparisons using the Bonferroni
adjustments.
12 Results were based on two-sided tests with a
p=0.01 significance level, except where indicated. Where
specific values were unknown, these cases were excluded
from the analysis when appropriate.
A forward stepwise binary logistic regression model was
used to evaluate the impact of age, stage, and comorbid
burdenondeterminationoftypeoftreatment,i.e.,theoddsof
“surgery, with or without other treatment” compared to the
odds of nonsurgical treatment (radiation and/or chemother-
apy). The Wald statistic was used to test significance.
Exponentiated estimates of the beta coefficients were
interpreted as the estimates for the effect (odds ratio) of a
particular variable, controlling for the other variables in the
equation. A receiver operating characteristic (ROC) curve
was created to examine the prediction results. The true-
positive probability was calculated to define the sensitivity
of the classification rule and the true-negative probability
was calculated to determine the specificity to summarize
how well the model performed.
Confidentiality
Data reported to the NCDB are retrospective in nature. No
patient or physician identifiers were collected as part of the
study. Case identification information (facility identification
number and local registry accession number) was collected
for administrative purposes only. Analyses were reported
only at the aggregate level to assist hospital cancer programs
with quality assurance, rather than used to make decisions
about individuals and their care.
The ACS has executed a business associate agreement
that includes a data-use agreement, with each of its CoC-
approved hospitals. Results reported in this study were in
compliance with the privacy requirements of the Health
Insurance Portability and Accountability Act of 1996 as
reported in the Standards for Privacy of Individually
Identifiable Health Information; Final Rule (45 CFR Parts
160 and 164).
Results
Treatment Volumes
Atotalof691cancerprogramswereincludedinthestudy:258
CHCP sites, 267 COMP sites, and 166 THCP sites. Although
37.3% of the programs were CHCPs, only 22% (n=1329) of
the cases were treated in this setting; 40.8% (n=2,468) of the
cases came from COMPs; and 37.2% (n=2,250) of the
patients came from THCPs. Community Hospital Cancer
Programs saw on average of 5.2 cases/year; COMPs, 9.2; and
THCPs 13.6. The THCPs treated more surgical patient on
average (7.6 cases) than either the COMPs (5.3 cases) or the
CHCPs (2.9 cases) (Table 1).
Patient Demographics
Men, 3,751(62%), and women, 2,296 (38%), were equally
distributed across hospital types. The mean age in years was
69.3 and the median age 71 (18–103 years). Significantly
more 70 and older patients were seen in CHCPs when
compared to COMPs or THCPs (p<0.01). Significantly
more 50 and younger patients were seen at THCPs when
compared with CHCPs and COMPs (p<0.01) (Table 2).
The study population included4,076 (67.4%)Caucasians,
827 (13.7%) African Americans, 533 (8.8%) Hispanic,
472 (7.8%) Asians, and 139 (2.3%) patients of other or
unknown racial or ethnic background. Significantly fewer
Caucasians were seen in THCPs when compared to
412 J Gastrointest Surg (2007) 11:410–420CHCPs and COMPs (p<0.01). THCPs saw significantly
more African Americans than the other two types of
cancer programs (p<0.01). Significantly more Asians were
seen at COMP hospitals when compared to CHCP hospitals
(p<0.01), but there was no significant difference when
comparing the proportion of Asians in COMPs to the
proportion found in THCPs.
A large percentage of this patient population did not
have a documented AJCC Stage reported (n=1,041,
17.2%). Of those patients with a documented stage, more
than 64.5% had advanced stage (stage III or IV) at
presentation. The largest subgroup had stage IV disease
(n=2,118, 35.0%). There were no significant differences in
the stage at presentation between the different types of
Table 1 Number and Percent of Cancer Programs, Number and Percent of Patients by Cancer Program, Mean Number and Range of All Cases
by Cancer Program Type, Number and Percent of Surgically Treated Cases, and Mean Number of Surgical Cases and Range by Cancer Program
Type
Community Cancer Centers Comprehensive Community Cancer Centers Teaching/Research Hospitals Total
Number (%) of cancer
programs
258 (37.3) 267 (38.6) 166 (24.0) 691
Number (%) of patients
in study
1,329 (22.0) 2,468 (40.8) 2,250 (37.2) 6,047
Mean number and range
of all cases
5.2 (1–39) 9.2 (1–49) 13.6 (1–55)
Number (%) of surgical
cases
673 (20.5) 1,369 (41.8) 1,235 (37.7) 3,277
Mean number and range
of surgical cases
2.9 (1–16) 5.3 (1–37) 7.6 (1–40)
Table 2 Patient Characteristics by Type Cancer Program
Community Cancer Center Comprehensive Cancer Center Teaching/Research Total
n (%) n (%) n (%) n (%)
Gender
Male 805 (60.6) 1,502 (60.9) 1,444 (64.2) 3,751 (62.0)
Female 524 (39.4) 966 (39.1) 806 (35.8) 2,296 (38.0)
Total 1,329 2,468 2,250 6,047
Age
<50 106 (8.0) 207 (8.4) 264 (11.7) 577 (9.5)
50–69 402 (30.2) 865 (35.0) 836 (37.2) 2,103 (34.8)
70 and older 821 (61.8) 1,396 (56.6) 1,150 (51.1) 3,367 (55.7)
Total 1,329 2,468 2,250 6,047
Race/Ethnicity
Caucasian 966 (72.7) 1,723 (69.8) 1,387 (61.6) 4,076 (67.4)
African American 143 (10.8) 278 (11.3) 406 (18.0) 827 (13.7)
Hispanic 120 (9.0) 206 (8.3) 207 (9.2) 533 (8.8)
Asian 78 (5.9) 218 (8.8) 176 (7.8) 472 (7.8)
Other 22 (1.7) 43 (1.7) 74 (3.3) 139 (2.3)
Total 1,329 2,468 2,250 6,047
AJCC stage
O 2 (0.2) 8 (0.3) 2 (0.1) 12 (0.2)
I 13 (1.0) 28 (1.1) 26 (1.2) 67 (1.1)
IA 105 (7.9) 210 (8.5) 182 (8.1) 497 (8.2)
IB 118 (8.9) 218 (8.8) 178 (7.9) 514 (8.5)
II 160 (12.0) 286 (11.6) 242 (10.8) 688 (11.4)
III 6 (0.3) 12 (0.5) 12 (0.5) 30 (0.5)
IIIA 156 (11.7) 347 (14.1) 337 (15.0) 840 (13.9)
IIIB 47 (3.5) 96 (3.9) 97 (4.3) 240 (4.0)
IV 427 (32.1) 856 (34.7) 835 (37.1) 2,118 (35.0)
Unknown 295 (22.2) 407 (16.5) 339 (15.1) 1,041 (17.2)
Total 1,329 2,468 2,250 6,047
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location of the primary cancer was the cardia 27.4% (n=
1,656), followed by the antrum 18.3% (n=1,107) and
stomach, not otherwise specified (NOS) 17.9% (1,080)
(Fig. 1). The distribution of tumor location was similar
among all these categories of treatment institution.
Diagnostic Testing
Diagnostic evaluation included computed tomography (CT)
of the abdomen (n=4,417, 73%) and pelvis (46.9%) over
all hospital types. The abdominal CT suggested a diagnosis
of cancer in 63.9% of patients at CHCP, 63.0% at COMP,
and 68.2% at THCP. The CT of the abdomen was more
likely to suggest cancer at the THCP when compared to the
COMP (p<0.01), but no significant difference was noted
between the THCP and the CHCP. Computed tomography
of the pelvis was suggestive for cancer in 36.9, 38.1, and
42.6% at CHCP, COMP, and THCP, respectively. The
differences across cancer programs were not significant
(p>0.01). Only 15.6% (n=946) of these cases were
evaluated with endoscopic ultrasonography. That procedure
was used more often at THCPs (33.5%) when compared
to both CHCP (13.8%) and COMP (17.6%) (p<0.01).
2-
18F-Fluoro-2-deoxy-D-glucose positron emission tomog-
raphy (F18-FDG-PET) was rarely used at any type of
hospital (4.6%). When done, THCPs were more likely to
use the F18-FDG-PET than CHCP for diagnostic testing
(p<0.01). No significant differences were noted between
THCP and COMP use.
Intraoperative Assessment
Staging laparoscopy was performed significantly more
often at THCPs (18.9%) than at COMPs (13.6%) or at
CHCPs (10.5%) (p<0.01). No significant differences were
seen between COMPs and CHCPs. Peritoneal lavage with
cytology for the assessment of occult peritoneal disease was
rarely used at THCPs, COMPs, and CHCPs with rates of
5.7, 4.3, and 2.7%, respectively. Significantly fewer perito-
neal lavages occurred at CHCPs when compared to THCPs
(p<0.01). No significant differences were found between
THCPs and COMPs.
Surgical Treatment
Surgical intervention was undertaken for 54.2% (n=3,277)
of the all patients in the study. At CHCP hospitals, 673
out of 1,329 (50.6%) patients were surgically treated, 1,369
out of 2,468 (55.5%) were surgical patients at COMP, and
1,235 out of 2,250 (54.9%) patients underwent surgery at
THCP. When surgeries were grouped as less extensive or
more extensive, significantly more extensivesurgeries were
performed at THCPs thanat CHCPs (p<0.01); however, no
significant difference was observed between COMPs and
THCPs (p>0.01). More specifically, the most frequently
recorded type of surgical resection was gastrectomy, NOS
(overall, 21.7%; CHCP, 26.0%; COMP, 20.5%; and THCP,
20.6%) followed by distal gastrectomy (overall, 16.2%;
CHCP, 15.6%; COMP, 17.3%; and THCP, 15.2%), and
partial or subtotal gastrectomy (overall, 13.3%; CHCP,
12.2%; COMP, 12.7%; and THCP, 14.6%). A near total or
total gastrectomy was uncommonly performed (overall,
5.7%; CHCP, 4.3%; COMP 5.7%; and THCP, 6.4%). After
pathologic analysis, 83.5% of the entire surgical patient
population had a resection with curative intent (R0
resection), whereas 16.5% had a palliative resection (R1
resection). The frequencies of R0 and R1 resections were
similar (CHCP, 81.2/18.8%, COMP, 84.6/15.4%, and THCP,
83.6/16.4%) among all institutions and not statistically
different between different types of institution (p=0.25).
Lymph node staging, a highly significant predictor of
outcome, was evaluated using the number of lymph nodes
examined after surgical resection. Analysis of at least 15
Figure 1 Location of cancer at presentation by cancer program types:
a Community Hospital Cancer Program (CHCP), b Community Hospital
Comprehensive Cancer Program (COMP), and c Teaching Hospital Cancer
Program (THCP). Location of lesions: cardia, funds, body, antrum, pyloric,
lesser curve, and greater curve by percent and others indicated by asterisk
(C168, overlapping lesions and C169, stomach, NOS).
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and exclusion of nodal metastases. Only 31.1% of patients
at CHCPs, 31.0% at COMPs, and 38.4% at THCPs had
more than 15 nodes examined (p<0.01). A large number of
patients from each hospital type had an unknown number of
lymph nodes pathologically evaluated (26.6% CHCP,
22.6% COMP, and 15.4% THCP), but THCPs had
significantly better documentation of lymph node evalua-
tion (p<0.05) (Fig. 2). A D1 lymphadenectomy with
removal of only perigastric nodes was noted in 56.7% of
surgically managed patients. Some patients had removal of
some lymph nodes that are included in D2 or D3 nodes but
most across all hospital types did not have a formal
extended lymphadenectomy (Table 3).
Morbidity and Mortality
The prevalence of operative morbidity, specifically for
postoperative hemorrhage, wound infection sepsis, and an
anastomotic leak, was similar across all hospital categories
(Table 4). Operative mortality, defined by 30-day mortality,
was different among the institution types. Teaching Hospi-
tal Cancer Programs had the lowest 30-day mortality at
5.5%, compared to 7.9% at COMPs and 9.9% at CHCPs
(Table 4). The proportional difference between THCPs and
COMPs was not significant (p>0.01), whereas, when
compared to CHCPs, THCPs had significantly fewer deaths
within 30 days of surgery (p<0.01). For those that died
within that 30-day period, no significant differences were
found across all hospital types for stage (p>0.01) or age
(p>0.01). In the logistic regression model stage was the
most significant predictor of 30-day postoperative death
(p=0.0001), followed by age (p=0.0001), and category of
hospital (p=0.004). Stage IV patients were 2.6 times (99%
confidence interval [CI]=1.6–4.3) more likely to die within
30 days of surgery; no other stage was significant (p>0.01).
Patients in CHCPs were almost twice as likely to die within
30 days when compared to THCPs (p=0.001). Race and
extent of surgery were not significant factors. The area under
the ROC curve defined by the logistic model was 0.69 (99%
CI=0.64–0.74), where 0.5 represents a nondiscriminatory
result. Long-term 5-year survival data are unavailable for this
patient population and will not be until the fall of 2007.
Neoadjuvant and Adjuvant Therapy
Approximately 38.9% of the surgical patients received
chemotherapy; 30.5% received radiation therapy. Neither
neoadjuvant radiation therapy nor chemotherapy was
frequently provided at all hospital types, but highest,
although not significant (p>0.01) at the THCPs when
compared to CHCPs and COMPs (Table 5). Patients more
frequently received adjuvant chemotherapy and radiation
than neoadjuvant chemotherapy or radiation therapy at all
the categories of hospitals. There were no statistically
significant differences in the frequency of treatment with
chemotherapy or radiation therapy by tumor stage between
the hospital categories.
Figure 2 Percent of lymph
nodes sampled at each hospital.
CHCP = Community Cancer
Center Program, COMP =
Community Hospital
Comprehensive Cancer
Program, THCP = Teaching
Hospital Cancer Program.
p<0.05 (asterisk).
Error bars: 95% CI.
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When examining the current status of gastric cancer patient
care in the US and seeking ways to improve survival,
looking to the East for guidance is a reasonable strategy.
The standards of gastric cancer therapy have largely been
set by the practices of Japanese physicians and surgeons, in
a large part, because of their large experience with this
disease. In Japan, there are 104,000 new cases annually in a
population of 128×10
6,
13 compared to the 22,000 cases
Table 4 Postoperative Mortality and Complications
Community Cancer Center Comprehensive Cancer Center Teaching/Research
n (%) n (%) n (%)
30-Day mortality
a
Yes 55 (9.9) 93 (7.9) 59 (5.5)
No 501 (90.1) 1,080 (92.1) 1,020 (94.5)
Bleeding
b
Yes 20 (4.2) 40 (3.9) 47 (5.1)
No 451 (95.8) 993 (96.1) 881 (94.9)
Wound infection
c
Yes 35 (7.4) 54 (5.2) 61 (6.6)
No 440 (92.6) 981 (94.8) 868 (93.4)
Sepsis
d
Yes 34 (7.1) 62 (6.0) 43 (4.7)
No 443 (92.9) 973 (94.0) 881 (95.3)
Anastomotic leak
e
Yes 32 (6.7) 68 (6.5) 64 (6.6)
No 447 (93.3) 979 (93.5) 884 (93.2)
Comparison of column proportions did not include the unknown values in calculations.
a30-Day mortality unknown, n=469
bBleeding unknown, n=845
cWound infection unknown, n=840
dSepsis unknown, n=841
eAnastomotic Leak unknown, n=803
Table 3 Lymph Nodes Sampled During Surgical Resection
Resected Community Cancer Center Comprehensive Cancer Center Teaching/Research
n (%) n (%) n (%)
Perigastric
a
Yes 367 (71.1) 775 (68.9) 715 (70.4)
No 149 (28.9) 350 (31.1) 301 (29.6)
Hepatic
b
Yes 21 (4.2) 68 (6.5) 70 (7.5)
No 478 (95.8) 979 (93.5) 867 (92.5)
Celiac
c
Yes 40 (7.9) 100 (9.5) 96 (10.1)
No 465 (92.1) 952 (90.5) 854 (89.9)
Splenic
d
Yes 14 (2.8) 49 (4.7) 52 (5.5)
No 481 (97.2) 988 (95.3) 887 (94.5)
Paraaortic
e
Yes 94 (18.8) 170 (16.8) 189 (20.2)
No 405 (81.2) 840 (83.2) 745 (79.8)
Comparison of column proportions did not include the unknown values in calculations.
aPerigastric unknown, n=620
bHepatic unknown, n=794
cCeliac unknown, n=770
dSplenic unknown, n=806
eParaaortic unknown, n=834
416 J Gastrointest Surg (2007) 11:410–420seen annually in the US in a population of 296×10
6,
1 an
incidence that is more than 10 times greater than that of the
US.
The high incidence seen in Japan has allowed the
Japanese to develop surgical and medical strategies to
improve mortality. However, several of the surgical
principles practiced in Japan are difficult to incorporate
into Western practices. Early detection programs in Japan
have led to a significant decrease in mortality but this has
not been replicated in the US because of the high cost to
benefit ratio associated with the much lower incidence of
gastric cancer in the US. A more controversial standard
Japanese practice is the extended D2, D3, or even D4
lymphadenectomy performed for gastric cancer. Whereas
extended lymphadenectomy has been associated with
improved survival in Japan, with retrospective analysis,
the value of this technique has not been proven in the West.
Wanebo et al.,
14 in a retrospective study from the US, as
well as Bonenkamp et al.
15 and Cuschieri et al.
16,i n
randomized controlled trials from The Netherlands and
Great Britain, respectively, have reported a lack of survival
benefit with D2 lymphadenectomy. Both Bokenkamp et
al.
15 and Cuschieri et al.
16 observed significantly higher
mortality rates among those patients that had a D2 resection
of 10 vs 4% and 13 vs 6.5%, respectively. The operative
mortality after a D2 resection is much lower in Japan with
reported rates below 2%.
17,18 Kodera et al. from Japan
reported an operative mortality rate of 0.8% from 523
patients in a D2 vs D3 study.
19
Studies examining large national databases have found
improved surgical mortality after gastrectomy for gastric
cancer at high-volume centers. A study examined using the
National Inpatient Sample reported on 23,690 hospitalized
patients with a hospital discharge code of gastric cancer and
any gastrectomy noted significant differences in mortality
among hospital types. Very-low-volume hospitals (<4
cases/year) had a mortality rate of 8.9% compared with a
rate of 6.4% seen at high-volume hospitals (>9 cases/
year).
20 In a study by Birkmeyer et al.
21 of the Medicare
population, the observed mortality rate was 13% at very-
low-volume centers (<5 cases/year) compared to 8.7% at
very-high-volume centers (>21 cases/year). Improved sur-
vival among high-volume hospitals was also reported in
Swedish
22 hospitals that treated >20 surgical patients a year
and German
23 hospitals that treated >50 patients/year.
The Japanese have also noted an association of lower
patient survival rates among gastric cancer patients treated
at low-volume centers when compared to high-volume
centers. Nomura et al.
9 analyzed a database of more than
55,000 patients and grouped them into the following time
periods: 1975–1979, 1980–1984, 1985–1989, and 1990–
1994. He found “positive relationships between hospital
volume and 5-year survival” but over time the survival
benefit seen at high-volume centers decreased and persisted
in comparison with the very-low-volume centers.
Not all authors, however, have observed improved
survival at high-volume centers. A Dutch study evaluated
the impact of patient volume on operative mortality and
found no differences. This study analyzed 1,987 gastric
cancer patients treated at 22 hospitals between 1987 and
1997.
24 A limitation of this study is the fact that only 1 of
the 22 hospitals was a university hospital and the others
were “general hospitals.” Many of the participating hospi-
tals were considered to be low-volume centers.
Interpretation of the Results
Our study had similar results to the aforementioned
American, Japanese, and European studies. In this study,
there was a marked improvement (>50%) in operative
mortality at higher volume centers (≥14 cases/year) when
compared to lowest volume institutions (≤5 cases/year). The
average 30-day postoperative mortality at the low-volume
community centers was almost 10%. The annual volume of
gastric surgeries performed seems to be inversely related to
30-day postoperative mortality. On average 2.9, 5.5, and 7.6
gastric surgeries were reported from CHCPs, COMPs, and
THCPs, respectively. Corresponding 30-day mortality was
Table 5 Radiation and Chemotherapy/Surgery Sequence
Community Cancer Center Comprehensive Cancer Center Teaching/Research
# (%) # (%) # (%)
Radiation
a
Neoadjuvant 23 (12.1) 53 (13.0) 68 (19.1)
Adjuvant 167 (87.9) 356 (87.0) 288 (80.9)
Chemotherapy
b
Neoadjuvant 36 (14.6) 71 (15.0) 87 (20.3)
Adjuvant 210 (85.4) 401 (85) 342 (79.7)
Comparison of column proportions did not include the unknown values in calculations.
aRadiation sequence unknown, n=43
bChemotherapy sequence unknown, n=128
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differences seen in postoperative morbidities such as wound
infection and hemorrhage by hospital category. The logisti-
cal model revealed three predictors of perioperative mortality:
stage IV disease, advanced age, and institution type. Patients
that had surgery at a CHCP were twice as likely to die
postoperatively compared to patients treated surgically at
THCPs. Among those that died, there were no significant
differences of stage or age at the different institutions.
Because the absolute differences in surgical case number
among the hospital types were not vastly different, this
observed difference in outcomes may be a reflection of the
infrastructure of the institution rather than individualized
surgeon skill. Centers affiliated with a medical school
might have more experience with caring for the critically ill
in the form of larger and better equipped intensive care
units, resident and fellow coverage, newer technology, and
more subspecialized physicians to help manage patient
care. Unfortunately, we could not analyze the infrastructure
for each hospital type nor look at surgeon-specific experi-
ence in this study as this was not a part of the study.
Clinical staging is affected by the sensitivity and
specificity of the diagnostic studies performed during the
preoperative evaluation. An assessment of staging at the
different institutions revealed some major differences.
Teaching hospitals were more likely to detect malignancy
on a CT of the abdomen and pelvis than the other two
hospital types. This might be a reflection on the quality of
CT scans obtained and the experience of the radiologists.
Preoperative utilization of endoscopic ultrasound was
higher at teaching hospitals, a predictable finding given
the recent adaptation of this technology and the expertise
required to interpret these images.
In terms of pathologic staging, Karpeh et al.
25 previously
reported that evaluation of more than 15 lymph nodes
allows a better estimate of patient survival. In fact, a study
by Smith et al.
26 found that overall survival was largely
dependent on the number of nodes examined and found an
increase in survival when up to 40 lymph nodes was
assessed. We found that teaching hospitals did a signifi-
cantly better job meeting this recommendation; however,
even at THCPs only 38.4% of patients had greater than 15
nodes assessed. The D1 lymphadenectomy was the most
common operation for of nodal dissection, probably as a
result of controlled Western surgical trials showing no
survival benefit from a D2 dissection. Only a limited
number of patients had any D2–D4 nodes resected and
usually without a standardized extended lymphadenectomy.
A notable observation was that the percentage of D2–D4
lymphadenectomy performed at THCPs was not higher
than what was observed at COMPs or CHCPs.
To improve and obtain accurate surgical staging of
gastric cancer patients, current practice will have to
improve and will be dependent upon both the excision of
nodes by the surgeon and their retrieval from the specimen
by the pathologist. Given so few patients had 15 or more
nodes removed at the time of surgery, regardless of hospital
type, this practice could be improved by surgeons and
pathologists working together to achieve the goal of
identifying at least 15 nodes followed by the proper
documentation of the microscopic evaluation of these nodes
in the pathology report. If intraoperative pathologic
evaluation of the surgical specimen is possible and the
lymph node sampling is inadequate, the surgeon should
excise additional lymph nodes.
A strength of this study is the large number of patients and
hospitals included in the study. This broad sampling of
hospitals leads to a close approximation of the current
practice of gastric cancer treatment in the US. The main
shortcoming is that many of the critical data categories had at
least 20% “unknown” responses, and may have biased the
reported results of this study. In addition, analysis of hospital
infrastructure or surgeon volume was limited by lack data
availability in the database. Another limitation is that the 5-
year survival information has not yet been documented;
these data will provide long-term outcome by type of
treatment center.
Conclusion
Data from the Gastric PCE project suggests that there is
significant room for improvement in the surgical manage-
ment of gastric cancer in the US. Most hospitals, regardless
of category, do not document the evaluation at least 15
lymph nodes necessary to meet AJCC standards. With a
little over one third of all patients having more than 15
lymph nodes examined, pathologic staging is less accurate
and results of surgical and adjuvant therapy are likely to be
worse. Significantly more patients had appropriate staging
with the recommended number of nodes included in the
lymphadenectomy at teaching centers than at nonacademic
centers. Thirty-day mortality rates after gastric cancer
resection were significantly lower at teaching centers,
further establishing the recommendation that complex
oncologic operations should be performed at high-volume
centers to obtain better patient outcomes, corroborating the
results of several previous studies. Long-term survival data
will provide more information on effectiveness of treatment
at each of the different institution types.
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DISCUSSION
Richard H. Bell, Jr. M. D. (Chicago Ill): Thank you, Dr.
Reid-Lombardo. That was a nice presentation. This report
deals with the thorny issue of where complex GI proce-
dures are best done and by whom, and this is not an
academic discussion, because in your data you suggest that
there are about 500 preventable operative deaths per year in
the United States for gastric cancer patients. The difficult
question for me in all of this is identifying what is about
large tertiary hospitals that results in better operative
outcomes for complex GI cases. I think if we are going to
argue for centralization, we need to understand the rationale
for doing that. It is obviously a contentious issue.
So in this respect, I was disappointed a little bit with the
way you examined your results, becaused you claimed that
surgical volume predicts good outcomes, but this was
really not a study of volume. You divided your hospitals
based on structure and not on volume. You divided the
hospitals based on their classification by the American
College of Surgeons. And although you didn’t show it,
there was data in the manuscript that showed there were
actually significant volume overlaps between the three
categories. It was certainly not a clean distinction by
volume. Some of the less complex hospitals in your study
did as many operations as the tertiary medical centers,
although their average number was smaller. So I thought
this study would have been more illuminating if, in
addition to what you look at, you had looked at volume
as an independent variable in addition to structure. You
actually have an unusual study here in that you can look at
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tertiary hospitals the better equipment, the higher per?
forming ICUs, the resident coverage, all of these things are
the primary driver of better outcomes.
From an educational point of view, this has implications
in the sense that it would not do any good to do a better job
of training community general surgeons to be more
proficient in gastrectomy if the community hospitals is
fundamentally a less capable environment for this type of
operation. You have the data to lok at both structure and
volume, and I wish you had done that perhaps in the future
manuscript you will. Thank you.
Kaye Reid-Lombardo, M. D. (Rochester, Minn)
Thank you, Dr. Bell. I definitely agree with you that it is
less about volume, especially with gastric cancer, because,
you are right, even at teaching hospitals the volumes are not
that high. I think it has more to do with the infrastructure at
each institution, as is being reported by many authors as
well. I thinkfactors such as ICU availability or the radiologic
availability at each institution have more of an impact than
the surgeon in and of him or herself. So I think this study will
allow us to further examine things like infrastructure and see
whatthedifferencesareandtomakebetterrecommendations
based on that examination.
Michael A. Choti, M. D. (Baltimore, Md) Dr. Reid-
Lombardo, I enjoyed your presentation and thank you for
the opportunity to have reviewed the manuscript in
advance. This is just another example of how the National
Cancer Database can be a useful tool for analyzing a variety
of cancer mangement question. This database is robust and
different from SEER or other databases. I encourage others
to utilize this resource.
I have two questions. The first, you report a surprisingly
low number of palliative gastrectomies, yet you define this
as margin positive resection and not based on symptomatic
indications. While it is uncommon to have both proximal
and distal positive margins, even in palliative resections, it
is more common to have noncurative or R2 gastrectomy. In
such cases the margins may be negative but residual disease
is left behind as nodes or peritoneal implants. Were you
able to see the difference between the margin positive and
R2 resection?
The second question relates to the number of lymph
nodes evaluated in this series. As you know, guidelines
recommend histologic evaluation of at least 15 nodes. It
was interesting how few gastrectomies in fact achieve
greater 15 nodes. This number is significantly less than
even colorectal cancer, where much attention has recently
been given. Do you think in this case it is the pathol?
ogist diligence as much as the extent of lymphadenec-
tomy that is the problem? Or are we setting the bar to
high with the recommendation of 15 or more nodes?
Thank you.
Dr. Reid-Lombardo: Thank you for questions. To
answer your first question, it aws difficult to analyze R2,
and so that is why we difficult to analyze R2, and so that is
why we evaluated based on margin status. I would have
expected a higher palliative rate as well. We could not
analyze that from the database. I think to improve on the
lymph node sampling , the pathologist and surgeon must
work hand in hand. The pathologist should analyze the
resected specimen at the time that the surgeon is still in the
operating room and provide feedback. If there are less than
15 nodes, then more node sampling should be done by the
surgeon. Now, I know the western studies have not shown
improved survival among patients with D1 and D2 rescted
nodes, but sampling more nodes would almost seem to me
to assure that we are doing a more extended lymphadenec-
tomy. One way that we can achieve that goal is to have
better discussion, and not only discussion, but the pathol-
ogy report should clearly indicate how many nodes have
been examined and how many are positive or negative.
Thank you.
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